Biotech Values

[DewDiligence]

Pharmasset is attempting to resuscitate an IPO
that withdrawn in 2006. They have a phase-3 drug
(Clevudine) for HBV and a phase-1drug (R7128)
for HCV. Their Nasdaq ticker symbol, should the
IPO go off, will be the catchy “VRUS.”

http://yahoo.reuters.com/news/articlehybrid.aspx?storyID=urn:newsml:reuters.com:20070322:MTFH67693_2...

>>
Pharmasset Readies IPO of 6M Shares @$12-$14

Thu Mar 22, 2007 5:47 PM ET

WASHINGTON, March 22 (Reuters) - Pharmasset Inc. on Thursday said it is planning 6 million shares for between $12 and $14 per share in an initial public offering.

The clinical-stage pharmaceutical company, which is focused on treating viral infections, said the underwriters will have the option to buy another $900,000 more shares to cover over-allotments.

Banc of America Securities LLC, UBS Investment Bank and JMP Securities will underwrite the IPO, according to an offering document filed with the U.S. Securities and Exchange Commission.

It is seeking a Nasdaq listing under the symbol VRUS .
<<